New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 16, 2012
21:40 EDTWDC, REGN, EQIX, ADI, VRSK, LMCA, DISCA, SBAC, LBTYA, CTRXStocks being added to the NASDAQ-100 Index in annual re-ranking
The NASDAQ OMX Group announced the results of the annual re-ranking of the NASDAQ-100 Index, which will become effective prior to market open on Monday, December 24. The following ten securities will be added to the Index: Analog Devices, Inc. (ADI), Catamaran Corporation (CTRX), Discovery Communications (DISCA), Equinix, (EQIX), Liberty Global (LBTYA), Liberty Media Corporation (LMCA), Regeneron Pharmaceuticals (REGN), SBA Communications Corporation (SBAC), Verisk Analytics(VRSK) and Western Digital Corporation (WDC).
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 19, 2015
10:02 EDTDISCAOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:29 EDTDISCADiscovery initiated with a Buy at Rosenblatt
Target $38.
March 18, 2015
12:09 EDTDISCASony announces launch of PlayStation Vue in New York, Chicago, Philadelphia
Subscribe for More Information
06:31 EDTDISCADiscovery, Viacom in talks to be on Apple TV service, WSJ reports
Subscribe for More Information
05:15 EDTEQIXEquinix selects Singapore as strategic location for Asia-Pacific data center
Equinix announced the grand opening of its third International Business Exchange, or IBX, data center, known as SG3, in Singapore. The company's flagship data center is the largest in Asia-Pacific and demonstrates Equinix's ongoing commitment to the growing market demand for premium data center services from financial and cloud companies in the region. Equinix additionally announced that Orange Carriers Singapore, a 100 percent subsidiary of Orange Group, global communications solutions provider, and Datapipe, a global leader in managed hybrid IT solutions for the enterprise, have chosen to deploy in SG3 as part of their global expansion.
March 17, 2015
08:04 EDTWDCWestern Digital decline overdone, says RBC Capital
Subscribe for More Information
March 16, 2015
08:23 EDTREGNPCSK9 data continues to impress, says Leerink
Subscribe for More Information
07:28 EDTWDCWestern Digital, Seagate estimates lowered on PC weakness at Jefferies
Subscribe for More Information
07:16 EDTREGNRegeneron Sanofi dupilumab drug can generate $6B+ in revenue, says Bernstein
Bernstein believes that dupilumab, a drug made by Regeneron and Sanofi, has shown strong efficacy in patients with severe atopic dermatitis. The firm notes that the drug is currently in pivotal trials involving patients with severe levels of other common diseases. The firm thinks the drug can generate $1.5B of revenue by 2018 and $3.8B by 2020. Bernstein keeps a $500 price target and Outperform rating on Regeneron.
06:40 EDTREGNPCSK9 studies show potential improvement in heart health, WSJ says
Subscribe for More Information
06:05 EDTVRSKGen Re selects AIR Worldwide's Touchstone platform
Subscribe for More Information
March 15, 2015
19:33 EDTEQIXWalgreens Boots Alliance to replace Equinix in NASDAQ-100 Index as of 3/23
Subscribe for More Information
13:04 EDTREGNSanofi, Regeneron announce publication of results of ODYSSEY long term trial
Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) today announced that 18-month results of a Phase 3 trial of Praluent, alirocumab, an investigational therapy, involving 2,341 high risk patients with hypercholesterolemia were published online in The New England Journal of Medicine. In the ODYSSEY LONG TERM trial, Praluent 150 mg every two weeks reduced low-density lipoprotein cholesterol by an additional 62% at week 24 when compared to placebo, the primary efficacy endpoint of the study, with consistent LDL-C lowering maintained over 78 weeks."These results demonstrated the durable efficacy for Praluent when added to maximally-tolerated statin therapy and further reinforce its generally consistent safety profile," said Jennifer Robinson, M.D., M.P.H., Director of the Prevention Intervention Center, Professor, Departments of Epidemiology & Medicine, College of Public Health at the University of Iowa. "Additionally, the post hoc analysis of major cardiovascular events represents an important finding for Praluent -- we look forward to results from the ongoing ODYSSEY OUTCOMES trial, which is prospectively evaluating the potential of Praluent to reduce cardiovascular events."
March 13, 2015
17:34 EDTEQIXDenbury Resources to replace Equinix in S&P 400 as of 3/20 close
Subscribe for More Information
17:26 EDTEQIXEquinix to replace Denbury Resources in S&P 500 as of 3/20 close
March 12, 2015
13:06 EDTWDCHP rises fractionally despite Barclays downgrade, Intel guidance cut
Subscribe for More Information
10:01 EDTVRSKOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Ally Financial (ALLY) upgraded at Evercore ISI... Amarin (AMRN) upgraded to Buy from Neutral at H.C. Wainwright... American Vanguard (AVD) upgraded to Buy from Hold at Topeka... Banc of California (BANC) upgraded to Outperform from Market Perform at Raymond James... CNOOC (CEO) upgraded to Buy from Underperform at BofA/Merrill... Five Below (FIVE) upgraded to Buy from Neutral at Dougherty... Fuel Systems (FSYS) upgraded to Buy from Hold at Lake Street... GNC Holdings (GNC) upgraded at Morgan Stanley... Horizon Technology (HRZN) upgraded to Buy from Hold at Wunderlich... Magnum Hunter (MHR) upgraded to Buy from Neutral at SunTrust... NCI Building (NCS) upgraded to Buy from Neutral at Citigroup... Shore Bancshares (SHBI) upgraded to Outperform from Neutral at Boenning & Scattergood... United Therapeutics (UTHR) upgraded at Argus... Verisk Analytics (VRSK) upgraded to Buy from Hold at Evercore ISI... Windstream (WIN) upgraded to Buy from Neutral at Citigroup... York Water (YORW) upgraded to Neutral from Underperform at Hilliard Lyons.
09:43 EDTWDCIntel revenue cut weighs on semiconductor names
Subscribe for More Information
08:14 EDTVRSKVerisk Analytics upgraded at Evercore ISI
As previously reported, Evercore ISI upgraded Verisk to Buy from Hold. The firm upgraded shares based on valuation and the accretive WoodMac acquisition. Price target raised to $81 from $77.
06:14 EDTVRSKVerisk Analytics upgraded to Buy from Hold at Evercore ISI
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use